The Evidence for Switching Therapy in Patients Who Are Intolerant to or Experience a Loss of Response to Initial Biologic Therapy

Medical treatment for inflammatory bowel disease (IBD) has continued to evolve over the last decade or so. Introduction of biologic therapies in the IBD armamentarium has led to a paradigm shift in the way IBD is now treated. This session will focus on reviewing the important factors that may be considered when switching a patient from one biologic agent to another.

Upon successful completion of this activity, participants should be able to:

• Review various factors that clinicians should consider when switching a patient from one biologic agent to another
• Discuss the likelihood of achieving remission after experiencing a loss of response to a biologic agent

This educational activity is designed for gastroenterologists and other health care professionals interested in or involved with the management of patients with inflammatory bowel disease.

Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

Temple University School of Medicine is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

It is the policy of Temple University School of Medicine, The Albert J. Finestone, M.D., Office for Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).

The information presented in this CME activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System, or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgement when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, US Food and Drug Administration-approved uses and any off-label uses.

David T. Rubin, MD, has been a consultant for Abbott Laboratories; Axcan Pharma Inc.; Given Imaging Ltd.; Procter & Gamble Pharmaceuticals; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; Shire US Inc.; and UCB, Inc. He has received grant/research support from Procter & Gamble Pharmaceuticals; Prometheus Laboratories Inc.; Salix Pharmaceuticals, Inc.; and Shire US Inc. He is a member of the speakers bureaus for Abbott Laboratories; Centocor, Inc.; Procter & Gamble Pharmaceuticals; Prometheus Laboratories Inc.; and Salix Pharmaceuticals, Inc.

 

Remo Panaccione, MD, has been a consultant for AstraZeneca, LP, Ferring, Abbott Laboratories, Schering-Plough Corp., Shire Pharmaceuticals, Centocor, Inc., Elan Pharmaceuticals, GlaxoSmithKline, UCB, Inc., Procter & Gamble Pharmaceuticals, Bristol-Myers Squibb Co. Speaker’s bureau: AstraZeneca, LP, Abbott Laboratories, Solvay, Axcan, Jansen, Schering-Plough Corp., Shire, Centocor, Inc., Elan Pharmaceuticals, Prometheus Laboratories, Procter & Gamble Pharma­ceuticals, Advisory board: Ferring, Abbott Laboratories, Schering-Plough Corp., Shire, Elan Pharmaceuticals, UCB, Inc., Procter & Gamble Phar­maceuticals. He has received grant/research support from: Ferring, Abbott Laboratories, Axcan, Jansen, Schering-Plough Corp., Centocor, Inc., Millenium Phar­maceuticals, Elan Pharmaceuticals, Procter & Gamble Pharmaceuticals, Bristol-Myers Squibb Co.

 

Scott E. Plevy, MD, has been a consultant for Abbott Laboratories; Callisto Pharmaceuticals, Inc.; Centocor, Inc.; Elan Pharmaceuticals, Inc.; enGene, Inc.; Genentech, Inc.; Johnson & Johnson; Procter & Gamble Pharmaceuticals; Schering-Plough Corporation; Shire US Inc.; and UCB, Inc. He has received grant/research support from Viamet Pharmaceuticals, Inc. He has received royalties from Prometheus Laboratories Inc.

Members of Temple University School of Medicine and HealthcareFirst have no commercial relationships to disclose.


Copyright 2010 Temple University School of Medicine